Novozymes acquires BioGaia Fermentation  

World's leading enzyme producer makes first acquisition in pharmaceutical field

Novozymes, the world's leading enzyme producer, has announced the acquisition for an undisclosed sum of Sweden-based pharmaceutical protein producer BioGaia Fermentation. The deal, which is due to be finalised mid 2002, marks Novozymes' first step into the pharmaceutical field. According to a press release from Novozymes, the acquisition gains the Danish company not only a European cGMP-certified production plant and a team of highly skilled employees, but also an established customer base. In 2001 BioGaia Fermentation generated a turnover of DKK 30 million (USD 3.6 million).


The acquisition is reportedly conditional upon official permits and final approval from a shareholder meeting of parent company BioGaia AB, which will take place before the end of this month. If everything goes to plan, Novozymes intends to use the plant to manufacture its own products such as hyaluronic acid and antimicrobial peptides, as well as for existing and future contract manufacturing. For further information visit >

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×